Results 141 to 150 of about 170,196 (315)
Clinical Pharmacology &Therapeutics, EarlyView.Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le +8 more
wiley +1 more source
Pharmacotherapy for Eating Disorders
, 2017 This chapter addresses the pharmacotherapy of the eating disorders (EDs). Many persons with EDs receive pharmacotherapy, but pharmacotherapy research for EDs has lagged behind that for other major mental disorders.
Nicole Mori +3 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Yoo Jin Jang +2 more
wiley +1 more source
Optimizing pharmacotherapy in elderly patients: the role of pharmacists
, 2015 Jeannie K Lee,1 Samah Alshehri,1,2 Hussam I Kutbi,1,2 Jennifer R Martin1,3 1Pharmacy Practice and Science, University of Arizona College of Pharmacy, Tucson, AZ, USA; 2Department of Clinical Pharmacy, King Abdulaziz University College of Pharmacy, Jeddah,
Alshehri S, Martin JR, Lee JK, Kutbi HI
core
Clinical Pharmacology &Therapeutics, EarlyView.Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo +4 more
wiley +1 more source
Precision medicine to identify, prevent, and treat pediatric obesity
Pediatric obesity is a growing health concern that has many secondary adverse health implications. Personalized medicine is a tool that can be used to optimize diagnosis and treatments of many diseases.
Tillman, Emma M., Mertami, Selsbiel
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Despite developments in supporting the identification and selection of fit‐for‐purpose registries, a translational gap remains between the original purposes of clinically focused registries and their current and future expected use in policymaking. This study aimed to assess the extent to which cancer‐focused registries collect essential data elements ...
Manon C. Wilpshaar +4 more
wiley +1 more source
Pharmacotherapy of neurogenic inflammation
An in-depth look of therapeutic strategizes that target neurogenic inflammation. Generated by reviewing scientific research papers and experiments that look at diseases that have neurogenic inflammation in their pathogenesis such as migraines, IBC ...
Qayyum, Muhammad Wasiq
core
[Pharmacotherapy in coronary artery disease]
, 2009 With the exception of anticoagulant therapy this article reviews pharmacotherapy for patients with coronary artery disease based on indications, clinical trials and current guidelines.
Schoenenberger, Andreas W +2 more
core
Clinical Pharmacology &Therapeutics, EarlyView.Plasma 4β‐hydroxycholesterol (4β‐OHC) normalized for the levels of its parent cholesterol (4β‐OHC/C) is an endogenous biomarker for hepatic CYP3A4. This study evaluated CYP3A4 activity longitudinally in individuals while their obesity status was changing. 4β‐OHC/C was measured pre‐surgery (n = 54) and 2 years after Roux‐en‐Y gastric bypass (n = 30) and
Nihan Izat +6 more
wiley +1 more source